STAT3 and hepatocellular carcinoma: Therefore, we conclude that celecoxib might serve as a therapeutic agent for HCC by suppressing the IL-6/STAT3 signaling pathway and could be combined with other chemotherapeutic drugs to overcome drug resistance.